Founded by Dr. Ulrike Kettenberger, Prof Dominique Pioletti, and Dr. Rgis Gauderon and incorporated in July 2020, flowbone leverages regenerative nanomedicine to transform the care of millions of patients with bone diseases and disorders, such as osteoporosis. Currently, flowbone is transferring its technology to the first commercial product for bone repair. The company will target the treatment of bone marrow lesions, a condition associated with knee osteoarthritis. The goals consist of stopping pain, slowing down the progression of the disease, and preserving joints. In addition to the CHF 2. 1 million seed round, flowbone benefits from non-equity-based grants and awards, totaling CHF 2. 2 million. The latest award received is the Healthy Longevity 2022 QuickFire Challenge from the National Academy of Medicine, which includes grant funding and access to mentorship from experts across the Johnson Johnson Family of Companies. Gatan Marti, serial entrepreneur and one of the business angels supporting flowbone, explains With aging population, fractures resulting from osteoporosis will significantly increase.
Date: 8Nov,2022
